12th Congress of the European Hematology ... - Haematologica

to 60 years (n=116, or 72%) received anthracycline + cytarabine + etoposide
as induction, followed by consolidation including intermediate dose
cytarabine + mitoxantrone, while those aged more than 60 (n=44, 28%)
were treated in induction/consolidation with fludarabine/cytarabine given
as continuous sequential infusion. Consolidation therapy followed by
G-CSF at 10 microg/sqm given from day 15 to the last apheresis was
used as mobilization regimen. The following variables were analyzed:
age > vs 60 years, de novo vs s-AML, anthracycline vs fludarabine based
induction treatment, cytogenetics at diagnosis, presence of FLT3 mutations
(either ITD or D835 mutation), WBC at diagnosis (more or less than
50×10 9 /L), number of courses (i.e. 1 or 2) needed for achievement of CR.
The above parameters were correlated to successful mobilization
(defined as collection of >2×10 6 /L). Overall, 137 patients (86%) had a successful
mobilization of stem cells, while 23 (14%) failed to mobilize.
The median number of CD34 + cells collected was 6.9×10 6 /L (range 2.1-
25). Either univariate or multivariate analysis (see Table 1) failed to
demonstrate significant influence on successful mobilization for any of
parameter which were considered into the study. More in detail, no
effect was observed as median number of CD34 + cell collection, median
number of apheresis, peak of SC in PB and median number of CD34 +
cells collected per single apheresis were concerned. In addition, none of
the above parameters was significantly related to hematopoietic reconstitution
after autologous stem cell transplantation in terms of WBC and
platelet recovery, while hematopoietic recovery was significantly related
to the number of CD34 + infused cells. We conclude that successful
mobilization in AML is unpredictable by using the variables analyzed in
our study.
Table 1. Multivariate analysis of different paramenters on mobilization.
0052
THE DETERMINATION OF LEUKEMIC PHENOTYPE AND MINIMAL RESIDUAL DISEASE IN
ACUTE MYELOID LEUKEMIA BY USING FLOW CYTOMETRY
P. Topcuoglu, K. Dalva, S. Meric, S. Sahin, M. Arat, M. Beksac
Ankara University, ANKARA, Turkey
The hematological remission in acute leukemia is defined as the
achievement of complete hematological recovery in peripheral blood
and the a decrease of leukemic blasts below 5%. The persistency of
malignant cells below this threshold level (